Miller VM. Why are sex and gender important to basic physiology and translational and individualized medicine?. Am J Physiol Heart Circ Physiol 306: H781-H788, 2014. First published January 10, 2014; doi:10.1152/ajpheart.00994.2013.-Sex refers to biological differences between men and women. Although sex is a fundamental aspect of human physiology that splits the population in two approximately equal halves, this essential biological variable is rarely considered in the design of basic physiological studies, in translating findings from basic science to clinical research, or in developing personalized medical strategies. Contrary to sex, gender refers to social and cultural factors related to being a man or a woman in a particular historical and cultural context. Unfortunately, gender is often used incorrectly by scientists and clinical investigators as synonymous with sex. This article clarifies the definition of sex and gender and reviews evidence showing how sex and gender interact with each other to influence etiology, presentation of disease, and treatment outcomes. In addition, strategies to improve the inclusion of female and male human beings in preclinical and clinical studies will be presented, and the importance of embedding concepts of sex and gender into postgraduate and medical curricula will be discussed. Also, provided is a list of resources for educators. In the history of medical concepts, physiologists have provided pivotal contributions to understanding health and disease processes. In the future, physiologists should provide the evidence for advancing personalized medicine and for reducing sex and gender disparities in health care.
and clinical investigators as synonymous with sex, is considered an essential topic in medical curricula related to cultural sensitivity in health care delivery to reduce health disparities among ethnic, racial, and socioeconomic groups. What, then, is the appropriate way to consider sex and gender as research variables and in medical curricula? And why are they important to basic physiology and to translational and individualized medicine? This article will address these questions by clarifying the definitions of sex and gender and by reviewing evidence showing how sex and gender interact to influence etiology, presentation, and treatment outcomes of diseases. In addition, strategies to improve the inclusion of female and males in preclinical and clinical studies will be presented, and discussion will include the importance of embedding concepts of sex and gender into postgraduate and medical curricula with a goal to improve the health of both women and men and thus reduce disparities in health care.
Sex and Gender: Are We Talking About the Same Thing?
The Institute of Medicine defines sex as "being male or female according to reproductive organs and the functions assigned by chromosomal complement (XX for female and XY for male)" (77) . That is, sex is biology. There are genetic variants in sex chromosomes, but these are rare and are not considered in this review. For example, XXY (or Klinefelter's syndrome) occurs in about 1 of 580 live male births, X monosomy (or Turner's syndrome) occurs in about 1 of 5,000 live births, XXX occurs in about 1 of 1,000 births, and XYY occurs in about 1 in 1,000 male births.
Every cell has a sex, which is determined by the presence of the complement of sex chromosomes. The nongonadal functions directed by the sex chromosomes are critical to the physiology of the organism (53, 70a ) and include such important functions as coagulation (65) , innate immunity (10, 12) , synthesis of norepinephrine (4, 17, 49) , androgen sensitivity (36) , energy metabolism (adiposity) (72) , blood pressure (29) , and apoptosis (32) . These nongonadal effects of the sex chromosomes coupled with gonadal effects through genomic actions of the sex steroids result in sex differences in gene expression in every cell (28, 31, 51, 56, 66, 76, 78, 79) . Thus the sex of cells in culture, in isolated tissues, and in whole animals cannot be ignored in the design of experiments.
Whereas sex is biology, as defined by the Institute of Medicine, gender is everything else (77) , including psychosocial and cultural factors. According to Ristvedt (62) , the term "gender" evolved over time being originally used in linguistics. In linguistics, gender was used to designate words as masculine, feminine, or neutral. This concept was exported into "sexual science" where it was used to define masculinity/ femininity (46) and then psychoanalytical writers used it to encompass "socially constructed" male/female differences (62) . Thus sex and gender became incorrectly synonymous. In the 1990s, even the author of this review published papers addressing "gender differences" in vascular function when in reality the studies were about "sex differences" (1, 6 -8, 43, 75) . Fortunately, the Institute of Medicine report clarified the definitions, and there are steady and consistent efforts to adopt and apply the term "sex" to biological factors and "gender" to psychosocial and cultural factors.
Interaction of Sex and Gender in Translational Science
Sex differences in physiology and pathophysiology can be classified in three general categories. First are conditions or diseases unique to one sex, such as conditions associated with reproduction. Second are conditions or diseases that have greater prevalence in one sex compared with the other. Third are conditions that have different age of onset, symptomatology, or response to treatment in one sex compared with the other. Examples of conditions related to cardiovascular diseases in each of these categories are shown in Table 1 . Other areas of physiology can generate similar lists that encompass diseases of the respiratory system, musculoskeletal system, immunological system, gastrointestinal system, renal/urological system, development, and behavior.
Sex is a basic variable in every cellular and integrated physiological experiment. Because sex is based on two distinct chromosomal configurations, analysis of data to determine sex differences should treat sex as a dichotomous variable.
Although gender is related to sex, gender is not a dichotomous variable even though it is often considered as such when data are collected from self-declaration of gender as male and female. Gender defines behavioral, psychological, and cultural characteristics that are expressed on a continuum. For example, masculine and feminine behaviors may be defined by sociocultural expectations (37) . What may be considered a neutral behavior in one culture, for example, driving or smoking, may be considered a masculine behavior in another culture. When behaviors are classified as aggressive or stoic for males compared with nurturing or expressive for females, males and females exhibit a range of scores that are distinct but overlap, i.e., a continuous variable (62) . Thus analysis of outcome data by self-reported gender alone may not provide all of the information needed to draw conclusions about behaviors that could affect disease risk factors, treatment efficacy, or outcomes if self -reporting of gender differs from the biological sex of the individual. The question then becomes, how does gender interact with sex to influence health and disease? Both sex and behaviors influenced by gender will affect physiology and pathophysiology. The relative contribution and interaction between biological sex and external sociocultural influences of gender is an ongoing topic of scientific inquiry. Sophisticated imaging modalities coupled with computational analysis showed sex differences in distinct connectivity between cerebral hemispheres and cerebellum of adolescent males and females of various ethnicities from the Philadelphia region of the United States (27) . These data provide additional support for the hypothesis that conceptual and motor behaviors develop at an early age and reflect underlying differences in biology of the sexes. This conclusion should not be surprising given that every cell has a sex and cellular function that is influenced by the genome and sex steroid milieu to which the cell is exposed (2, 3) .
For physiological studies using material derived from experimental animals, the issue of "gender" is mostly irrelevant, except for specific studies of behavior (22) , as the environment in which experimental animals are bred and raised is controlled. However, gender will impact results of experiments in which tissues and cells are derived from humans, clinical human studies, as well as those studies of health disparities and health outcomes in humans. For example, risk of death from cardiovascular disease was lower in men with a high "femininity" behavioral score, compared with men with a high "masculinity" behavioral score (25) . Some risk factors associated with gendered behaviors, such as smoking history and alcohol consumption or occupations, are captured on inclusion criteria or evaluations for clinical studies or in the medical record by a quantitative scale such as pack years of smoking. Gene expression and cellular regulatory pathways in isolated cells obtained from such individuals may reflect epigenetic changes brought about by lifelong tobacco use or exposure or exposure to xenobiotics or other environmental pollutants (herbicides, industrial and automotive smog, radiation, industrial or occupational-related chemicals, e.g., organic solvents, dyes, aerosols, asbestos). For cells and tissues obtained from commercial sources and biobanks, such information may not be available. However, at a minimum it is critical for the accurate interpretation of experiments to acknowledge that the sex of the cells or tissues may matter and could influence the results and to consider the hormonal status of the tissue donor which if unknown, could be surmised in part by age of the donor (sexually immature child, adolescent, adult of reproductive age, or senior).
In addition to sex differences in potential exposure to disease risk factors, differences in sociocultural attitudes such as ethnicity, occupation, marital/partner status, income, years of education, etc., may affect access to medical care and compliance with treatment. Furthermore, the type of cardiovascular pathology, symptoms (Table 1 ) and response to treatment including response to therapies (48), i.e., aspirin (61) and statins (21) and to modifiable cardiovascular risk factors such as smoking cessation, diet, and exercise are influenced by the underlying biology, i.e., sex (13, 50, 55, 60) . In an era where health outcomes will be assessed from "big data" sets, it may be appropriate to exclude the category of gender and to include the category of sex together with more specific criteria that capture continuous and quantifiable variables constituting behavioral and cultural aspects of gender that are considered risk factors for disease. In Europe and Canada, the term genderbased medicine or gender differences is used more consistently to define medical conditions and health outcomes than the term sex-based medicine. Neither of these terms sex-based or gender-based medicine incorporates the totality of parameters influencing an individual's health status. However, their use represents a critical first step in acknowledging and quantifying parameters that influence health and movement toward embedding concepts of sex and gender into all aspects of health care, i.e., "individualized medicine" that encompasses both sex and gender.
Sex, Gender, and Policy in Scientific Publication and Research Funding
As mentioned in the Introduction, the NIH Revitalization Act of 1993 mandated the inclusion of women in studies of humans. However, the number of women included in drug and device trials remains low (14, 15, 19, 26) . The reasons for low participation of women are many (38) , including that some trials investigate conditions that are more common in men, for example heart failure with reduced ejection fraction. However, even in studies of conditions occurring with similar prevalence in women and men, participation by women ranged from 25-45% (40) . Some studies inadvertently exclude women because of restrictive inclusion criteria based on parameters that have a sex differential, such as size or normative blood parameters (16, 59) or that women are simply not asked to participate (57) .
The percentage of women enrolled in a trial may affect interpretation of the results. For example, the incidence of type II diabetes with the use of statin therapy was found to be proportional to the percentage of women enrolled in the trial: in a woman-only trial, the risk was 42%, whereas the risk was negligible (14%) in trials enrolling only men (21) . Thus, to individualize treatment options, a discussion between the health care provider and patient should include discussion of risk versus benefits that are specific to the sex of the individual. Therefore, it is critical that data from mixed sex trials be analyzed by sex and those results reported even if they are negative. It is just as critical to identify under what conditions, systems, responses, mechanistic pathways, etc., are the same between the sexes as to identify those which are not. However, reporting results by sex in clinical trials remains low (27a). It is critical that data be reported by sex rather than only accounting for sex as a confounding variable so that sex-specific outcomes from multiple studies could be evaluated by metaanalysis. Such sex-specific analyses form the basis for evidence-based medical decisions and are necessary to optimize individualized treatment strategies for men and women (48) .
The inability to reproduce many basic science experiments and to translate those results to the clinical arena is a concern (74) . Solutions proposed to improve reproducibility of results have focused on statistical issues in experimental design and analysis (go.nature.com/oloeip) and the lack of consistent quality systems such as reagents and assays used in different laboratories: http://gbsi.org/sites/default/files/uploads/pdf/the_case_for_standards.pdf (77a) . Methods sections of papers should provide sufficient information, including the sex of the experimental animal, so that another investigator can reproduce the experiment. Reporting of sex in basic science studies is abysmal and in many cases the sex of the material is not reported at all (66, 70, 81) . Given the lack of reporting of the sex of experimental material, an additional consideration would be for more rigorous monitoring and requirements for reporting of sex of the biological material. Gene expression and cellular processes vary by sex as discussed above, thus analyzing data from mixed groups of males and females in human studies or mixed groups of male and female cells or genetically manipulated mice may mask a treatment effect if the particular response is upregulated or positive in one sex and downregulated or negative in the other. As with the reported results with side effects of statin medications (21), other results derived from mixed populations of males and females may be influenced by the relative proportion of each sex used in the experiment.
Studying cellular mechanistic pathways in only one sex and assuming that the same regulatory pathways apply to the other sex is common in the scientific literature. Some examples include pathways involved in vascular remodeling, atherosclerosis, oxidative stress, and immune function (11, 18, 20, 30, 33-35, 39, 45, 52, 58, 64, 67-69, 71, 73, 80) . However, such assumptions are not appropriate given the present knowledge of sex differences in prevalence, symptomatology, and disease outcomes. Use of nondescripted nouns such as "mice," "humans," "cultured endothelial cells," etc., does not provide the same information as "female mice," "endothelial cells derived from a 65-yr-old male," etc. Specification of sex may affect the interpretation and translation of results derived from basic science studies that are needed to design clinical trials. Several professional societies including the American Physiological Society (41) and the Endocrine Society (9) (see http://genderedinnovations.stanford.edu for an up-to-date list of editorial policies for other journals) have editorial policies requiring reporting of the sex of the experimental material. Although the main onus is on the authors, peer reviewers, Associate Editors, and Editors share responsibility to ensure that policies are enforced.
To reduce disparities in health outcomes between men and women, it is essential for scientists and clinicians to consider sex differences as one of the underlying physiological mechanisms of disease. More research is needed to identify regula- (Table 2) . Currently, there are no requirements to include or address rationale for use of material from only one sex in applications funded by the NIH. Although identification of the number and sex of animals used in basic science studies and other conditions relative to their husbandry are required in the "Vertebrate Animal" section of NIH applications, it is not required to discuss sex and gender relative to outcomes of long-term goals of the research plan or to the scientific validity of choice of the experimental material. For example, would it be scientifically appropriate to develop an animal model of pulmonary hypertension only in male animals when in humans, pulmonary hypertension is more prevalent in females than males. A typical reason cited for not including both male and female animals in preclinical and mechanistic basic studies is cost. However, the cost of identification of sex differences in discovery experiments may be minimal compared with the cost and time wasted by developing an experimental model or therapeutic approach based on one sex that does not reflect disease expression in humans, fails clinical testing, or has to be withdrawn from the market due to adverse events in a mixed study population of men and women. For example, 8 out of 10 drugs withdrawn from the market between 1997 and 2001 were due to adverse events in women (24) . The first medications intended for use in both sexes to have different dosage recommendations for women and men came in May 2013 for zolpidem-containing drugs. The Federal Drug Administration approved labeling changes lowering the recommended dosage of these drugs for women due to increased side effects in women. One proposal to eliminate sex discrimination in basic research for conditions that are not sex specific would be to adopt principles of Title IX directed to eliminate sex discrimination in education to biomedical research (63) .
Scientific review panels for funding agencies usually do not respond favorably toward studies that explore sex differences, classifying such studies as "descriptive." There is some limited attention to this problem by the federal government. The Office of Research on Women's Health (ORWH) developed and designed an innovative, interdisciplinary-targeted funding mechanism that integrates basic, clinical, and translational investigation into sex and gender differences: Specialized Centers of Research (P50 SCOR mechanism). The range of topics for the Centers was derived from three sources: the Institute of (Table 3) . Requirements for the SCORs include a minimum of three ORWH is the major funder of the SCORs, but the ORWH is only a small fraction of the overall NIH budget. Although funding for SCORs is also provided by six National Institutes of Health Institutes and Centers and the Federal Drug Administration, the major portion of the NIH budget focuses predominantly on basic biomedical research in males. The SCORs represent initial steps in bringing attention to the need for research on sex differences in physiological processes and translational medicine. Clearly, there is a need for expansion of this program to reflect a broader range of diseases showing sex differences and for development of new funding sources directed at understanding basic and preclinical biological mechanisms for sex differences to advance translational, individualized medicine.
Embedding Concepts of Sex and Gender into Postgraduate and Medical Curricula
Evidenced-based medicine is built on results from basic, human, and clinical studies. Results of these studies need to be included in postgraduate and medical curricula to ensure development of sex-based evidence for individualized medical decision making. In a small case study conducted at Mayo Clinic, although fourth year medical students were aware of some sex differences in drug metabolism, they reported that such information was not translated into patient care (42) . A consensus statement from thought-leaders in medical education agrees that concepts of sex and gender will best be embedded throughout the postgraduate training and not as discrete units (44) . The challenge is to provide sufficient mechanistic data and outcome data in all aspects of training which is a work in progress. Educators are reluctant to begin a time and laborintensive process of developing entirely new programs and materials. However, resources are beginning to accumulate that can be incorporated and customized to fit into existing programs (Table 4 ). Efforts to expand these resources are underway and should hasten curricula change.
Conclusion
Individualized medicine requires viewing the patient through a sex and gender lens as a first step toward personalizing care and potentially improving outcomes. However, the evidence upon which to base sex-specific decisions needs to be improved. The first step toward accomplishing this goal is for basic scientists to provide more data regarding mechanistic and regulatory processes which are similar and which differ between males and females. In addition, there is continued need for more scientific journal editors to institute editorial policies and for those who do, to enforce these policies that require reporting and analysis of data by sex and gender. Furthermore, increased support of sex difference research by funding agencies is needed, and funding agencies should develop requirements for inclusion of female animals in basic science and women in translational studies and clinical trials. Physiologists have consistently made pivotal contributions to understanding regulatory processes in health and disease. In the future, their contributions will continue to form the basis for advancing personalized medicine. As educators, they will pass on their discoveries to future basic and clinical researchers and health care providers by embedding concepts of sex and gender differences throughout revised curricula. When sex and gender are included as essentials for scientific excellence in research and education, health disparities between women and men will be reduced. 
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